Biotech Values

[DewDiligence]

BAX/MNTA FoB collaboration: MNTA has the contractual right to opt for profit and expense sharing (rather than receiving royalties on sales) for compounds #3, #4, #5, and #6 when the US IND is filed for compound #3. (Compound #3 in this context means the replacement for M511, which MNTA is now developing on its own.)